BenjaminBakallMDPhD

Ophthalmology • Phoenix, AZ

Retinal Disease

Medical retina/Inherited retinal dystrophies

Join to view full profile

Dr. Bakall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bakall's full profile

Already have an account?

Office
1750 E Glendale Ave
Phoenix, AZ 85020
Phone+1 602-242-4928

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Medical Retina, 2011 - 2013
University of Arizona College of Medicine-TucsonResidency, Ophthalmology, 2008 - 2011
University of Arizona College of Medicine2007 - 2008
University of Arizona College of MedicinePost-Doctoral Fellowship, 2005 - 2007
Uppsala University Faculty of MedicineClass of 2005
Uppsala UniversityPhD, 2003
University of Iowa Hospitals and ClinicsResidency, Ophthalmology

Certifications & Licensure

AZ State Medical License 2013 - 2026
IA State Medical License 2011 - 2018
OH State Medical License 2010 - 2011
American Board of Ophthalmology Ophthalmology

Publications & Presentations

PubMed

122 citations
Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice
Precious J. McLaughlin, Benjamin Bakall, Jiwon Choi, Zhonglin Liu, Takako Sasaki
Human Molecular Genetics. 2007-12-15
183 citations
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Benjamin Bakall, James C. Folk, H. Culver Boldt, Elliott H. Sohn, Edwin M. Stone
American Journal of Ophthalmology. 2013-07-01
1 citations
Emerging Disease of the Desert: Rise of West Nile Virus Chorioretinitis in Arizona.
Jamie L Odden, Dillan Patel, J Shepard Bryan, Benjamin Bakall, Rima Patel
Journal of Vitreoretinal Diseases. 2023-11-23

Press Mentions

Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GADecember 15th, 2023
Ocugen, Inc. Announces the First Patient Dosed in Phase 3June 21st, 2024
Ocugen Doses First Patient with Gene Therapy for Retinitis Pigmentosa in Phase 3 TrialJuly 7th, 2024